Strategic alliances, such as that between Bristol Myers Squibb and SystImmune, are increasingly becoming prevalent as firms share resources to speed up development. These alliances are needed for accelerating BsADCs through clinical development more quickly, leveraging complementary skills to bring more potent cancer treatments. The Future Direction of Bispecific Antibody Drug Conjugates The report foresees a rosy future for the bispecific antibody drug conjugates market, with strong growth fueled by advancing technology and mounting clinical success. Researchers are likely to continue to optimize bispecific antibody drug conjugates design, with an emphasis on multi-target strategies that target multiple cancer antigens or pathways of the tumor microenvironment.